Compare DexCom, Inc. (DXCM) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Shell PLC — how do they compare? DexCom, Inc. trades at $78.38 (market cap $28.06B), while Shell PLC trades at $85.25 (market cap $228.96B). The key difference: Shell PLC is far larger — about 8.2× DexCom, Inc.'s market cap, and Shell PLC pays a 3.69% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SHEL | |
|---|---|---|
Market Cap | $28.06B | $228.96B |
Sector | Health | Energy |
52-Week High | $89.53 | $94.15 |
52-Week Low | $54.84 | $70.28 |
Enterprise Value | $27.03B | $281.49B |
Dividend Yield | — | 3.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Shell (SHEL) trades at $84.41, up 0.51% on the day, with a bullish technical signal and strong analyst support. Recent Q1 2026 earnings beat expectations at $2.44 EPS, though revenue has trended down from $381.3B in 2022 to $266.9B in 2025. The stock shows attractive valuation with a P/E of 13.18 and P/S of 0.93, while news highlights the ARC Resources acquisition approval and Venezuela gas field development plans.
Outlook remains positive given high analyst buy ratings (69%) and a $122.20 consensus price target, but risks include declining operating cash flow, Middle East production disruptions, and exposure to volatile energy markets. Earnings growth and strategic acquisitions are key catalysts for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
